Nikhil I. Khushalani

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor et al. · The Lancet Oncology · 2015 · 2.7K citations

Medicine, Oncology, Pharmacotherapy +16

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Neurology, Oncology +14

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott et al. · JAMA Oncology · 2015 · 656 citations

Life Sciences, Immunology, Oncology +15

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 525 citations

Medicine, Immunology, Oncology +17